PATENT CLAIM ANALYSIS

Application Number: 15951929
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "134100"]

Abstract:
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.

Claim (Index 37):
The method of  claim 1 , wherein the administration of the recombinant follistatin protein results in muscle regeneration, increased muscle strength, increased flexibility, increased range of motion, increased stamina, reduced fatigability, increased blood flow, improved cognition, improved pulmonary function, inflammation inhibition, reduced muscle fibrosis, and/or reduced muscle necrosis.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 91.0
- Lexical Diversity: 1.4
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14762373', '15075051', '15081629', '14254560', '12893976']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7592794332480456
- 35 USC 102 Novelty (BERT): 0.7068585580803756
- Combined Prediction Score: 0.7540373457312786
- Mean Citation Score: 463.8713
- Max Citation Score: 744.8266
- Similarity Product: 740.7704394123912

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test